Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center

Journal of Clinical Microbiology

Volumn 35, Issue 8, 1997, Pages 2061-2067

  Emery, Christopher L ^a   Weymouth, Lisa A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATION; ENTEROBACTERIACEAE; HOSPITAL CARE; NONHUMAN; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE;

EID: 0030835823     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.35.8.2061-2067.1997     Document Type: Article

References (32)

1. Bauernfeind, A., Y. Chong, and S. Schweighart. 1989. Extended broad spectrum β-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 17:316-321.
2. Bingen, E. H., P. Desjardins, G. Ariel, F. Bourgeois, P. Mariani-Kurkdjian, N. Y. Lambert-Zechovsky, E. Denamur, A. Philippon, and J. Elion. 1993. Molecular epidemiology of plasmid spread among extended broad-spectrum β-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital. J. Clin. Microbiol. 31:179-184.
3. Brun-Buisson, C., P. Legrand, A. Philippon, F. Montravers, M. Ansquer, and J. Duval. 1987. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet ii:302-306.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
5. Caron, F., L. Gutmann, A. Bure, B. Pangon, J.-M. Vallois, A. Pechinot, and C. Carbon. 1990. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended broad-spectrum TEM-3 β-lactamase. Antimicrob. Agents Chemother. 34:2070-2074.
6. Casellas, J. M., and M. Goldberg. 1989. Incidence of strains producing extended spectrum β-lactamases in Argentina. Infection 17:434-436.
7. Cormican, M. G., S. A. Marshall, and R. N. Jones. 1996. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E test ESBL screen. J. Clin. Microbiol. 34:1880-1884.
8. Dudley, M. 1995. Bacterial resistance mechanisms to β-lactam antibiotics: assessment of management strategies. Pharmacotherapy 15(1 Pt. 2):9S-14S.
9. Fantin, B., B. Pangon, G. Potel, F. Caron, E. Vallee, J.-M. Vallois, J. Mohler, A. Bure, A. Philippon, and C. Carbon. 1990. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like β-lactamase. Antimicrob. Agents Chemother. 34:581-586.
10. Jacoby, G. A., and P. Han. 1996. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J. Clin. Microbiol. 34:908-911.
11. Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35:1697-1704.
12. Jacoby, G. A., and G. L. Archer. 1991. New mechanisms of bacterial resistance to antimicrobial agents. N. Engl. J. Med. 324:601-612.
13. Jarlier, V., M.-H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867-878.
14. Katsanis, G. P., J. Spargo, M. J. Ferraro, L. Sutton, and G. A. Jacoby. 1994. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum β-lactamases. J. Clin. Microbiol. 32:691-696.
15. Lofland, D., and L. A. Weymouth. Unpublished data.
16. Meyer, K. S., C. Urban, J. A. Eagan, B. J. Berger, and J. J. Rahal. 1993. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Intern. Med. 119:353-358.
17. National Committee for Clinical Laboratory Standards. 1993. Performance standards for antimicrobial disk susceptibility tests. 5th ed. Approved standard M2-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
19. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing. 6th informational supplement. M100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. Naumovski, L., J. P. Quinn, D. Miyashiro, M. Patel, K. Bush, S. B. Singer, D. Graves, T. Palzkill, and A. M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob. Agents Chemother. 36:1991-1996.
21. Philippon, A., S. Ben Redjeb, G. Fournier, and A. Ben Hassen. 1989. Epidemiology of extended-spectrum β-lactamases. Infection 17:347-354.
22. Philippon, A., R. Labia, and G. Jacoby. 1989. Extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 33:1131-1136.
23. Quinn, J. P., D. Miyashiro, D. Sahm, R. Flamm, and K. Bush. 1989. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 33:1451-1456.
24. Rice, L. B., J. D. C. Yao, K. Klimm, G. M. Eliopoulos, and R. C. Moellering, Jr. 1991. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob. Agents Chemother. 35:1243-1244.
25. Rice, L. B., S. H. Willey, G. A. Papanicolaou, A. A. Medeiros, G. M. Eliopoulos, R. C. Moellering, Jr., and G. A. Jacoby. 1990. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. 34:2193-2199.
26. Sanders, C. C., and W. E. Sanders, Jr. 1992. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15:824-839.
27. Sirot, D. L., F. W. Goldstein, C. J. Soussy, A. L. Courtieu, M. O. Husson, J. Lemozy, M. Meyran, C. Morel, R. Perez, C. Quentin-Noury, M. E. Reverdy, J. M. Scheftel, M. Rosembaum, and Y. Rezvani. 1992. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year study in France. Antimicrob. Agents Chemother. 36:1677-1681.
28. Smith, C. E., B. S. Tillman, A. W. Howell, R. N. Longfield, and J. H. Jorgensen. 1990. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase. Antimicrob. Agents Chemother. 34:1290-1293.
29. Spencer, R. C., P. F. Wheat, T. G. Winstanley, D. M. Cox, and S. J. Plested. 1987. Novel β-lactamase in a clinical isolate of Klebsiella pneumoniae conferring unusual resistance to β-lactam antibiotics. J. Antimicrob. Chemother. 20:919-927.
30. Thomson, K. S. 1995. Improved detection of extended-spectrum β-lactamases (ESBLs) from disk diffusion susceptibility tests, abstr. C-87, p. 16. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C.
31. Thomson, K. S., and C. C. Sanders. 1992. Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob. Agents Chemother. 36:1877-1882.
32. Thornsberry, C. 1995. Trends in antimicrobial resistance among today's bacterial pathogens. Pharmacotherapy 15(1 Pt. 2):3S-8S.